Samir Parekh, MD
Selinexor and venetoclax (Venclexta) have each made waves in recent clinical trials of patients with relapsed/refractory multiple myeloma. As novel agents emerging in landscape, they provide potential to improve response rates that are currently lacking with standard treatment options.
"The impact of these drugs has been pretty amazing in the salvage of patients with relapsed and refractory multiple myeloma," said Samir Parekh, MD, in a presentation during the 2018 OncLive®
State of the Science Summit™ on Multiple Myeloma.
At the meeting, Parekh, associate professor of Medicine, Mount Sinai Health System, discussed the excitement of selinexor and venetoclax as possible additions to the myeloma treatment landscape.
Selinexor is an oral small molecule inhibitor that blocks the transport of proteins between the nucleus and the cytoplasm, Parekh explained. This agent inhibits XPO1, an overexpression of which promotes tumor suppressor protein dislocation and proto-oncogene translation.
... to read the full story